

# Index

## A

airway smooth muscle cells (ASMC), 90

ALX/FPR2 receptor, 223

arachidonate 15-lipoxygenase-1 orthologs (ALOX15)

bioactivities of, 50

catalytic multiplicity

leukotriene synthase activity, 71–72

lipohydroperoxidase activity, 70–71

lipoxygenase activity, 65–70

degree of homology, of mammalian, 62

enzymology

human, 57–59

murine, 60–61

nonhuman primates, 59–60

porcine, 56

rabbit, 54–55

multiplicity, 49

perspectives, 72–73

structural biology

pig, 64

rabbit, 62–64

arachidonic acid (AA)

leukotrienes, 31, 32

lipoxygenation, 102

metabolism, 102

oxygenation, 61

oxygen insertion, 1, 2

p12-LOX, 166

aspirin induced asthma (AIA), 42

asthma, 200

atherosclerosis

animal models

omega-3 supplementation, 115

targeting 5-LO/FLAP, 111

targeting 12/15-LO, 113

targeting LT receptors, 113

targeting LXA<sub>4</sub> receptor, 114

effects of 5-LO knock-out, 112

effects of 12/15-LO knock-out, 114

effects of omega-3 supplementation, 116

E-series resolvins signaling, 111

expression and metabolism, 108

LT signaling, 109

LXs signaling, 109, 110

pathophysiology and clinical

context, 107

atopic dermatitis, 173

ATP, 15

## B

broken helix, 10

## C

cancer

breast cancer, 134

colorectal cancer, 138

hemato-oncological malignancies, 141

inhibitors and mitogenic effects, 145

lacking therapeutic efficacy, 146

pancreatic cancer, 133

prostate cancer, 137

chemokine-like receptor 1, 224

chronic inflammatory diseases, 90

coactosin-like protein (CLP), 12

cysteinyl-leukotrienes (cysLTs)

bioactions, 38

classical bioactions of, 39

cysteinyl-leukotrienes (cysLTs) (*cont.*)  
 elicit, 38  
 LTC4S, 41

## D

DDM. *See* Dodecylmaltoside (DDM)  
 diacylglycerides, 16  
 Dicer, 12  
 diHETEs, 188  
 DNA methylation, 19  
 docosahexaenoic acid (DHA), 85  
 dodecylmaltoside (DDM), 40  
 D-series resolvins  
   LO-driven, 217  
   LX, 221–223  
   receptors, 225  
   RvD1 and AT-RvD1, 221–223

## E

electron paramagnetic resonance  
 (EPR), 10  
 endogenous PUFA, 198  
 eosinophil chemoattractants, 193  
 eosinophilic diseases, 200  
 epidermis-type LOX-3 (eLOX-3), 168  
 E-series resolvins  
   LO-driven, 216–217  
   LX, 221  
   receptors, 225–226  
   RvE1, 219–221

## F

FLAP. *See* 5-lipoxygenase-activating protein  
 (FLAP)

## G

GC-boxes, 20, 21, 56  
 glutathione peroxidases, 92  
 granulocytes, 192  
 GSH molecule, 40

## H

helicobacter pylori, 90  
 hemostasis, 86, 89  
 12(S)-HETE, 87  
 human 15-lipoxygenase-2, 167  
 human ALOX15, 57  
 human GPR32, 225

5-hydroxyeicosanoid dehydrogenase  
 (5-HEDH), 187, 189  
 12-hydroxyeicosatetrenoate (12-HETE), 5, 87

## I

inflammation  
   classical cardinal signs, 213  
   injury and wound healing, 170  
   oxylipins on, 89  
   resolution response, 212

## L

leukotriene, 5  
   biosynthesis, 8, 14  
   formation, 18  
 leukotriene A<sub>4</sub> (LTA<sub>4</sub>), 186  
 leukotriene A4 hydrolase (LTA4H)  
   aminopeptidase activity, 33  
   catalytic mechanism, 36  
   cellular location, 33  
   crystal structure, 32, 34  
   drug target, 37  
 leukotriene C4 synthase (LTC4S)  
   drug target, 41  
   MAPEG members, 39  
   regulation, 39  
   topology, 38  
 leukotriene synthase activity, 71, 72  
 lipohydroperoxidase  
   activity, 70  
   mechanistic scheme, 66  
 lipoxin A4 receptor, 223  
 lipoxins (LX)  
   biological actions  
     D-series resolvins, 221–223  
     E-series resolvins, 221  
     lipoxins, 218  
   mechanisms of action  
     D-series resolvins receptors, 225–226  
     E-series resolvins receptors, 225–226  
     receptor identification and cell  
       expression, 223–224  
 5-lipoxygenase (5-LO), 162  
   discovery, 7  
   domains, 10  
   gene expression, 19  
     DNA methylation determines  
       expression, 19  
     effect of trichostatin A, 20  
     possible regulation by alternative  
       splicing and by miRNA, 22

- upregulation by TGF $\beta$  and 1,25(OH)  
2D3, 21
- vitamin D responsive elements, in  
promotor, 21
- interacting proteins
  - coactosin, 12
  - dicer, 12
  - FLAP, 11
- in leukotriene biosynthesis, 8
- regulation, of enzyme activity, 13
  - ATP, 15
  - Ca<sup>2+</sup>, 14
  - cell membranes and PC, 15
  - diacylglycerides, 16
  - leukotriene formation, gender-related
    - differences, 18
  - phosphorylation, 17
  - redox regulation, 16
  - subcellular localization, 18
- pathway, 186
- structure of, 10
- 5-lipoxygenase activating protein (FLAP), 11, 31
- 12-lipoxygenase (12(S)-LOX), 85
  - regulation, oxylipin
    - exposure, 92, 93
  - signal outcome, 93
- lipoxygenases (LOXs)
  - activity, 65, 68
    - biomembranes, 69
    - cholesterol esters, 69
    - fatty acids, 65
    - free fatty acids, 68
    - lipoproteins, 69
    - oxygenation of phospholipids, 69
  - arachidonic acid
    - metabolism of, 102, 103
    - omega 3 fatty acids, 104
  - atherosclerosis
    - animal models, 111, 113–115
    - E-series resolvins signaling
      - implications, 111
      - expression and metabolism, 108
      - LT signaling, 109
      - LXs signaling
        - implications, 109, 110
    - pathophysiology and clinical context, 107
  - catalytic property, 1
  - ChemR23, 107
  - clinical implications
    - anti-LTs, 120
    - omega 3 fatty acids, 121
  - epidermis-type lipoxygenase 3, 168
  - family, 84
  - FPR2/ALX, 106
  - future direction, 147
  - GPR32, 106
  - human 15-lipoxygenase-1, 165
  - human 15-lipoxygenase-2, 167
  - inflammatory skin diseases, 172
    - atopic dermatitis, 173
    - psoriasis, 172
    - systemic sclerosis, 173
  - intimal hyperplasia, 117
    - LT receptors, 118
    - LX-signaling in smooth muscle cells, 119
    - pathophysiology and clinical context, 117
    - resolvin-signaling in smooth muscle cells, 119
  - LT receptors, 104
    - mechanistic scheme, 65
  - metabolism of omega-3 fatty acids, 105
  - mouse 8-lipoxygenase, 167
  - multiplicity, 49
    - bacterial genes and LOX-isoforms, 53
    - human genes and LOX-isoforms, 49
    - mouse genes and LOX-isoforms, 50
    - zebrafish genes and LOX-isoforms, 51
  - oxylipin effect, 86
  - oxylipins in inflammation, 89
  - physiological and pathophysiological
    - roles, 5
  - in platelets, 84
  - platelet-type 12-LOX, 166
  - regulation, 2
  - 12R-lipoxygenase, 168
  - skin
    - cancer, 174
    - inflammation, injury and wound
      - healing, 170
    - metabolites in human and mouse, 162
    - 12R-LOX/eLOX-3 role, 169
    - structural and metabolic functions, 160
  - tumorigenesis role
    - breast cancer, 134
    - colorectal cancer, 138
    - hemato-oncological malignancies, 141
    - inhibitors and mitogenic effects, 145
    - lacking therapeutic efficacy, 146
    - pancreatic cancer, 133
    - prostate cancer, 137

LO-driven LX, 215–216

LO-driven Rv

D-series resolvins, 217

E-series resolvins, 216–217

maresins, 218

(Neuro)protectins, 217, 218

## M

Maresins, 218

membrane-Associated Proteins in Eicosanoid  
and Glutathione Metabolism  
(MAPEG), 39

mouse 8-lipoxygenase, 167

murine ALOX15 orthologs, 60

## N

(neuro)protectins, 217

neutrophils, 11, 192

## O

omega-3 fatty acids, 93

oxoeicosanoid (OXE) receptor

antagonists, 199

expression, 196

signaling mechanisms, 196

structural requirements for activation, 197,  
198

5-Oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid  
(5-Oxo-ETE)

biological activities, 198

cellular synthesis regulation, 190

5-HEDH

distribution, 189

properties, 188

substrate selectivity, 187

transcellular biosynthesis, 189

leukocytes effects

granulocytes, 192

monocytes, 194

metabolism, 191

OXE receptor, 194, 195

antagonists, 199

expression, 196

signaling mechanisms, 196

structure-activity relationships, 197

potential roles, 202

asthma, 200

cancer, 201

eosinophilic diseases, 200

synthesis pathways, 190

Oxylipins, 88, 91

## P

phosphorylation, 17

platelet-activating factor (PAF), 33

platelets, 86, 89

hemostatic and immune functions of, 84

hemostatic role, 83

influencing matters, for 12(S)-LOX signal  
outcome, 93

lipoxygenases

oxylipin effect, 86

inflammation, 89

12(S)-LOX, 89

mechanism for regulation, 88

original characterization of, 86

pro-inflammatory role, 84

regulation, of 12(S)-LOX oxylipin  
exposure, 92

trans-cellular regulation, 90

platelet-type 12-LOX (p12-LOX), 166

polymorphonuclear leukocytes (PMNs), 22,  
32, 214

polymorphonuclear neutrophils (PMN), 111,  
170, 213

polyunsaturated fatty acids (PUFA), 1, 8, 84,  
165, 168, 190, 213

porcine ALOX15 (pigALOX15), 56,  
64, 69

Pro-Gly-Pro (PGP), 33, 34

prothrombotic observations, 87

psoriasis, 172

PUFAs. *See* Polyunsaturated fatty acids  
(PUFA)

## R

rabbit ALOX15 (rabALOX15)

arachidonic acid oxygenation, 55, 72

calcium concentrations, 55

fatty acid oxygenation, 55, 68

reaction kinetics, 54

structural biology

crystal structure, 62

solution structure, 63

redox cycle, 16

resolvins (Rv)

biological actions

E-series resolvins, 221–223

lipoxins, 218

mechanisms of action

D-series resolvins receptors, 225–226

E-series resolvins receptors, 225–226

receptor identification and cell  
expression, 223–224

**S**

## skin

- cancer, 174
  - inflammation, injury and wound healing, 170
  - metabolites in human and mouse, 162
  - 12R-LOX/eLOX-3 role, 169
  - structural and metabolic functions, 160
- specialized pro-resolving mediators (SPM)
- inflammatory resolution, 212
  - lipoxygenases, 213
  - pro-resolution lipid mediators, biosynthesis of, 213
- systemic sclerosis, 173

**T**

- thrombosis, 86
- trichostatin A, 20
- trimeric functional unit, 40
- tumorigenesis
- breast cancer, 134
  - colorectal cancer, 138
  - hemato-oncological malignancies, 141
  - inhibitors and mitogenic effects, 145
  - lacking therapeutic efficacy, 146
  - pancreatic cancer, 133
  - prostate cancer, 137

**Z**

- zebrafish genome, 52